Tonix Pharmaceuticals Hld

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied DNA Sciences

Chimerix

Geovax Labs

iShares Genomics Immunology and Healthcare ETF

SIGA Technologies

Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfizer (NYSE: PFE ), BioNTech (NASDAQ: BNTX ), and Moderna (NASDAQ: MRNA ), which have developed the Covid-19 vaccines that have now become household names.

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher

Phase 1 Study of TNX-801, a Vaccine in Development for the Prevention of Monkeypox and Smallpox, Expected to Initiate in First Half 2023 in Kenya; the U.S. has Declared Monkeypox a Public Health Emergency

Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

Aethlon Medical

Chembio Diagnostics

E-Home Household Service Holdings Ltd

NanoViricides

10 monkeypox stocks and monkeypox penny stocks to watch The post 10 Top Monkeypox Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Monkeypox Stocks To Watch Right Now

Monkeypox penny stocks to watch this week. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 4 Monkeypox Stocks To Watch This Week

AMTD International Inc

MediaCo Holding Inc.

Here's what you need to know about buying penny stocks on August 2nd The post Best Penny Stocks to Watch Before Market Open on August 2nd  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Watch Before Market Open on August 2nd

Clinical-stage biotechnology firm Tonix Pharmaceuticals (NASDAQ: TNXP ) – which focuses on novel therapeutics and diagnostics – is making waves today, announcing the issuance of a patent. Specifically, the U.S. Patent and Trademark Office (or USPTO) granted a patent on TNX-1900 for the indication of treating pain, including that stemming from migraine headaches.

Tonix Pharmaceuticals (TNXP) Stock Surges 15% on Patent News

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Pain

The stock price of Tonix Pharmaceuticals (TNXP) fell by 10.16% in the previous trading session. This is why.

Tonix Pharmaceuticals (TNXP) Stock: Why It Fell 10.16%

Phase 1 Clinical Study Expected to be Initiated in Kenya in the First Half of 2023

Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection

BioNTech SE

Moderna

Monkeypox cases are significantly growing during the past few months, especially catalyzed by an increase in international travel. On July 23, WHO declared the Monkeypox spread as a global health emergency, indicating the agency's high degree of concern around the severity of the disease and its spread.

Moderna 2.0: 3 Stocks To Play The Potential Monkeypox Pandemic

VistaGen Therapeutics

Here's what you need to know about trading penny stocks on July 26th The post What to Know About Buying Penny Stocks on July 26th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on July 26th

If you thought monkeypox was a fad, you might want to reconsider.

Hot Penny Stocks To Watch As Monkeypox Gets WHO GHE Designation

CHATHAM, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Sina Bavari, Ph.D. as its new Executive Vice President, Infectious Disease Research and Development. In this role, Dr. Bavari will be responsible for leading Tonix's development of its growing infectious disease pipeline and will serve as a key member of the Company's executive leadership team. Dr. Bavari will be based in Frederick, Md. and, as part of his role, will oversee scientific development at Tonix's Infectious Disease R&D Center located there.

Tonix Pharmaceuticals Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and Development

Naloxone-Free Formulation of Tianeptine is an Extended-Release Tablet that Includes Inactive Ingredients and Compression Properties Designed to Confer Abuse Deterrence

Tonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive Disorder

CHATHAM, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will present at the World Orphan Drug Congress USA 2022 being held July 11-13, 2022 at the Hynes Center in Boston, MA. The presentation will take place on Monday, July 11, 2022 at 2:00 p.m. ET.

Tonix Pharmaceuticals Announces Presentation at the World Orphan Drug Congress USA

Mustang Bio

9 Meters Biopharma

Here's what you need to know about trading penny stocks on June 23rd The post What to Know About Buying Penny Stocks on June 23rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on June 23rd

CHATHAM, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 2,500,000 shares of Series A convertible redeemable preferred stock and 500,000 shares of Series B convertible redeemable preferred stock. Each share of Series A and Series B preferred stock has a purchase price of $9.50, representing an original issue discount of 5% of the $10.00 stated value of each share. Each share of Series A and Series B preferred stock is convertible into shares of the Company's common stock at an initial conversion price of $4.00 per share. Shares of the Series A and Series B preferred stock are convertible at the option of the holder at any time following the Company's receipt of shareholder approval for an increase to the authorized shares of common stock of the Company from 50 million to 150 million. The Company will be permitted to redeem the Series A preferred stock at its option upon the fulfillment of certain conditions and subject to certain limitations. The Company and the holders of the Series A and Series B preferred stock also entered into a registration rights agreement to register the resale of the shares of common stock issuable upon conversion of the Series A and Series B preferred stock. Total gross proceeds from the offerings, before deducting discounts, placement agent's fees and other estimated offering expenses, is $30 million.

Tonix Pharmaceuticals Announces Pricing of $30 Million Private Placement of Convertible Redeemable Preferred Stock

The ADC is Expected to Accelerate Clinical-Scale Manufacturing of Live Virus Vaccines, Including Vaccines for Monkeypox, Smallpox and COVID-19

Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Advanced Development Center (ADC) for Vaccine Programs in Massachusetts

Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital

Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2022 American Transplant Congress

Abbott Labs

Emergent BioSolutions

Inovio Pharmaceuticals

SIGA Technologies (SIGA) may lead on the list of monkeypox stocks that could soar, but Bavarian Nordic seems to be leading the sales race. The post 7 Monkeypox Stocks That May Take Off in Q2 appeared first on InvestorPlace.

7 Monkeypox Stocks That May Take Off in Q2

Oral Presentation Describes Activity of Wnt/β-Catenin Signaling Pathway Inhibitors Against SARS-CoV-2 in Cell Culture and in an Animal Model Oral Presentation Describes Activity of Wnt/β-Catenin Signaling Pathway Inhibitors Against SARS-CoV-2 in Cell Culture and in an Animal Model

Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 4th Symposium of the Canadian Society for Virology

Poster Presentation Includes Preclinical Data from Tonix's Program to Develop a Vaccine for Monkeypox and Smallpox Poster Presentation Includes Preclinical Data from Tonix's Program to Develop a Vaccine for Monkeypox and Smallpox

Tonix Pharmaceuticals Announces Presentation on TNX-801 Vaccine Protection Against Monkeypox at the 4th Symposium of the Canadian Society for Virology

CHATHAM, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the 2022 BIO International Convention being held June 13-16, 2022 in San Diego, CA. The presentation will take place on Monday, June 13, 2022 at 3:45 p.m. PT in Theater 4 of the San Diego Convention Center.

Tonix Pharmaceuticals Announces Presentation at the 2022 BIO International Convention

Tonix Pharmaceuticals Corp (NASDAQ: TNXP) was up 25% after announcing that the US Patent and Trademark Office gave it a US Patent No. 11,342,896 on May 31, 2022.

Tonix Pharmaceuticals jumps 25%, and here is why

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower by 6.03% to $2.96 during Thursday's pre-market session. The company announced Thursday that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq.

What's Going On With Tonix Pharmaceuticals Shares Today?

News for Tonix Pharmaceuticals Hld Stock (TNXP)